SyntekaBio, Inc. (KOSDAQ:226330)
South Korea · Delayed Price · Currency is KRW 3,405.00
+10.00 (0.29%)
At close: Apr 17, 2026
SyntekaBio Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -17,378 | -7,213 | -11,398 | -4,506 | -14,803 |
Depreciation & Amortization | 2,023 | 2,254 | 1,762 | 1,473 | 1,158 |
Loss (Gain) From Sale of Assets | 25.27 | 5.73 | - | -0.13 | - |
Asset Writedown & Restructuring Costs | 46.91 | 1.26 | 72 | 20.25 | - |
Stock-Based Compensation | 625 | 572.84 | 779.78 | 793.17 | 364.78 |
Provision & Write-off of Bad Debts | - | - | - | - | -0.27 |
Other Operating Activities | 6,132 | -5,977 | 778.98 | -5,813 | 6,984 |
Change in Accounts Receivable | -847.59 | 0.06 | 0.83 | 53.97 | -32.15 |
Change in Unearned Revenue | - | - | - | -171.11 | - |
Change in Other Net Operating Assets | -1,277 | -152.95 | -73.97 | -360.5 | 288.52 |
Operating Cash Flow | -10,650 | -10,509 | -8,078 | -8,511 | -6,040 |
Capital Expenditures | -11.01 | -5,707 | -9,364 | -8,389 | -7,479 |
Sale of Property, Plant & Equipment | 14 | - | - | 0.13 | - |
Sale (Purchase) of Intangibles | -56.51 | -109.79 | -65.61 | -368.06 | -69.14 |
Investment in Securities | - | - | - | 39,000 | -560 |
Other Investing Activities | 76.28 | 20 | -0 | -9.96 | 4.52 |
Investing Cash Flow | 22.76 | -5,797 | -9,430 | 30,233 | -8,104 |
Short-Term Debt Issued | 14,107 | - | - | - | - |
Long-Term Debt Issued | 18,480 | 10,000 | 10,000 | - | 25,000 |
Total Debt Issued | 32,587 | 10,000 | 10,000 | - | 25,000 |
Short-Term Debt Repaid | -14,107 | - | - | - | - |
Long-Term Debt Repaid | -27,327 | -1,730 | -8,228 | -263.16 | -402 |
Total Debt Repaid | -41,434 | -1,730 | -8,228 | -263.16 | -402 |
Net Debt Issued (Repaid) | -8,847 | 8,270 | 1,772 | -263.16 | 24,598 |
Issuance of Common Stock | 23,765 | 262 | 12 | 174.13 | 414.15 |
Other Financing Activities | -0 | -0 | -0 | - | 196.51 |
Financing Cash Flow | 14,919 | 8,532 | 1,784 | -89.03 | 25,209 |
Foreign Exchange Rate Adjustments | -11.79 | 171.5 | 48.83 | -0.08 | -6.44 |
Miscellaneous Cash Flow Adjustments | - | 0 | - | - | - |
Net Cash Flow | 4,280 | -7,602 | -15,674 | 21,634 | 11,058 |
Free Cash Flow | -10,661 | -16,216 | -17,442 | -16,899 | -13,520 |
Free Cash Flow Margin | -310.88% | -13413.89% | -14133.89% | -6926.24% | -4269.46% |
Free Cash Flow Per Share | -684.02 | -1063.33 | -1218.35 | -1250.52 | -1004.13 |
Cash Interest Paid | 942.54 | - | - | - | - |
Cash Income Tax Paid | -55.89 | -130.56 | 42.79 | 67.64 | -8.71 |
Levered Free Cash Flow | -10,391 | -19,769 | -9,212 | -1,735 | -15,780 |
Unlevered Free Cash Flow | -8,615 | -18,514 | -8,977 | -952.52 | -15,621 |
Change in Working Capital | -2,124 | -152.9 | -73.15 | -477.65 | 256.37 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.